Table 1 Developmental potential of miNT and SCNT embryos generated from mtDNA depleted and nondepleted donor cells in the presence and absence of TSA.

Donor cell	Method	TSA	Fused (%)	No. embryo	Cleaved (%)*	No. (%)* embryo developed to
Donor cell	Method	TSA	Fused (%)	No. embryo	Cleaved (%)*	8-Cell	Morula	Blastocyst
Nondepleted	miNT	−	168/180 (93.3 ± 1.3)^a	161	146 (90.7 ± 1.9)^ab	103 (64.0 ± 8.9)	63 (39.1 ± 5.3)^ab	62 (38.5 ± 5.7)^a
Nondepleted	SCNT^†	−	254/271 (93.7 ± 1.6)^a	248	216 (87.1 ± 0.3)^ab	152 (61.3 ± 2.2)	91 (36.7 ± 2.9)^ab	89 (35.9 ± 3.4)^a
Depleted	miNT	−	172/208 (82.7 ± 3.7)^b	168	142 (84.5 ± 3.5)^ab	75 (44.6 ± 1.7)	43 (25.6 ± 2.6)^bc	34 (20.2 ± 2.0)^b
	SCNT^†	−	189/247 (76.5 ± 1.7)^b	174	137 (78.7 ± 5.0)^b	77 (44.3 ± 4.6)	36 (20.7 ± 3.4)^c	35 (20.1 ± 3.8)^b
	miNT	+	182/231 (78.8 ± 0.9)^b	161	146 (90.7 ± 3.2)^a	97 (60.2 ± 8.6)	44 (27.3 ± 2.0)^bc	38 (23.6 ± 1.2)^b
	SCNT^†	+	173/230 (75.2 ± 3.1)^b	163	144 (88.3 ± 3.6)^ab	98 (60.1 ± 6.6)	58 (35.6 ± 5.0)^ab	57 (35.0 ± 4.6)^a
	PA	−	N/A	164	143 (87.2 ± 2.9)^ab	93 (56.7 ± 9.2)	71 (43.3 ± 2.5)^a	71 (43.3 ± 2.5)^a

miNT, mitochondrial supplementation in combination with SCNT; SCNT: Somatic cell nuclear transfer;
PA: Parthenogenetic activation.
−, absence of TSA; +, presence of TSA; TSA, Trichostatin A.
*Percentages calculated from the number of embryos that cleaved and developed to each stage.
^†Data from our previous report⁵⁰. Values are mean ± SEM.
Four replicates per treatment.
Different superscripts within a column indicate significant differences (P < 0.05, ANOVA with Duncan’s multiple range test using SAS version 9).

Quick links

Search